West Pharmaceutical Services Inc. ($WST) Stock Forecast: Down 5.2% Today

What is West Pharmaceutical Services Inc.?

A leading company in injectable drug packaging, West Pharmaceutical Services (WST), is valued at $18 billion and has played a vital role in global vaccine distribution during the pandemic.

Why is West Pharmaceutical Services Inc. going down?

WST stock is down 5.2% on Mar 10, 2026 16:51

• The bearish movement in WST stock may be linked to uncertainty surrounding an upcoming CEO transition, as Eric Green, credited with significant company growth, prepares to retire.
• Despite strong Q4 2025 earnings and positive 2026 guidance, concerns about the leadership change and its potential effect on future growth may have prompted investor caution.
• Projected growth in the pharmacy blister packaging market presents potential opportunities for WST, but investor focus on internal company dynamics rather than broader industry trends is evident.
• Valuation concerns, including a high P/E ratio relative to industry norms, could be contributing to the downward pressure on WST stock as investors reevaluate the company's future post-Green's retirement announcement.

WST Price Chart

WST Technical Analysis

WST News

West Pharmaceutical CEO to step down after 11 years at $18B company

Eric Green, CEO of West Pharmaceutical Services, an Exton-based company specializing in packaging for injectable drugs, is retiring after 11 years. Green notably led the company's efforts in supplying packaging for global vaccine distribution during the pandemic. The company is valued at $18 billion.

https://www.bizjournals.com/philadelphia/news/2026/03/10/west-pharmaceutical-services-ceo-eric-green-retire.html

Assessing West Pharmaceutical Services (WST) Valuation After Earnings Beat And Upbeat 2026 GLP 1 Guidance

West Pharmaceutical Services (WST) reported strong Q4 2025 earnings and provided positive 2026 guidance, emphasizing its GLP-1 exposure and plans for shareholder returns. Despite recent share price pressure, the company is seen as potentially undervalued with a fair value of $338.57, driven by expected revenue growth, margin improvement from new automated delivery devices, and GLP-1 market opportunities. However, its current P/E of 36.2x is higher than industry averages, suggesting a full valuation that could limit upside if growth expectations are not met.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-wst/west-pharmaceutical-services/news/assessing-west-pharmaceutical-services-wst-valuation-after-e

Pharmacy Blister Packaging Market to Witness Stunning Growth

Coherent Market Insights has released a detailed report on the "Pharmacy Blister Packaging Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033." The report provides a comprehensive analysis of market dynamics, including competition, geographic distribution, growth potential, and key success factors. It highlights major market players, segmentation by pharmacy type, and offers critical insights for businesses, investors, and strategists.

https://www.openpr.com/news/4418542/pharmacy-blister-packaging-market-to-witness-stunning-growth

West Pharmaceutical CEO Eric Green to retire in second half 2026

West Pharmaceutical Services, Inc. announced that CEO Eric M. Green plans to retire in the second half of 2026 once a successor is found. Green has served as President and CEO since 2015, during which time the company more than doubled sales and achieved a 350% total shareholder return. The company reaffirmed its guidance and noted recent strong financial performance, including exceeding Q4 2025 earnings expectations and declaring a quarterly dividend.

https://ca.investing.com/news/company-news/west-pharmaceutical-ceo-eric-green-to-retire-in-second-half-2026-93CH-4503614

West Pharmaceutical (WST) CEO to Retire, Leadership Transition Planned for 2026

West Pharmaceutical Services (WST) announced that CEO Eric M. Green plans to retire in the latter half of 2026, leading to a planned leadership transition. The company has begun a search for his successor and reaffirmed its financial guidance from February 12, 2026. West Pharmaceutical, a key supplier to the pharmaceutical industry, shows strong financial health despite some margin declines.

https://www.gurufocus.com/news/8692100/west-pharmaceutical-wst-ceo-to-retire-leadership-transition-planned-for-2026

Trending Today

West Pharmaceutical Services Inc. Price History

10.02.2026 - WST Stock was down 5.2%

• The bearish movement in WST stock may be linked to uncertainty surrounding an upcoming CEO transition, as Eric Green, credited with significant company growth, prepares to retire.
• Despite strong Q4 2025 earnings and positive 2026 guidance, concerns about the leadership change and its potential effect on future growth may have prompted investor caution.
• Projected growth in the pharmacy blister packaging market presents potential opportunities for WST, but investor focus on internal company dynamics rather than broader industry trends is evident.
• Valuation concerns, including a high P/E ratio relative to industry norms, could be contributing to the downward pressure on WST stock as investors reevaluate the company's future post-Green's retirement announcement.

13.01.2026 - WST Stock was up 5.2%

• The bullish movement in WST stock today can be attributed to the company's robust Q4 2025 results and optimistic 2026 guidance, which exceeded market expectations and showcased strong revenue growth driven by high-value product components, GLP-1 demand, and biologics recovery.
• Despite concerns raised in previous quarters about slipping net profit margins and trailing revenue growth, the company's forecasted profit for 2026 above estimates, fueled by strong demand for drug components, has instilled confidence in investors and contributed to the stock's positive performance.
• The tension between bullish growth narratives and financial challenges seems to have been alleviated by the company's updated outlook, emphasizing organic net sales growth and highlighting the positive impact of underlying demand and product mix on its future financial prospects.
• Overall, WST's stock surge today reflects investor optimism surrounding the company's ability to capitalize on the expanding GLP-1 market, strategic investments in innovation, and the promising outlook for its high-value product components in the healthcare industry.

04.01.2026 - WST Stock was up 5.0%

• West Pharmaceutical Services (WST) witnessed a strong bullish movement in the market today, with the following factors contributing to this positive trend:
• Analysts maintaining a "Buy" consensus rating for WST, setting an average target price of $335.78, reflecting confidence in the company's future performance.
• Truist Financial Corp significantly increased its stake in WST by 73.7% in the third quarter, indicating strong institutional investor confidence in the company's growth prospects.
• Despite a slight decrease in the average one-year price target for WST, the new target still represents a notable 23.61% increase from the latest closing price, showcasing optimism about the company's potential.
• The recent launch of DuPont's new Liveo C6-8XX Liquid Silicone Rubber series for healthcare applications might have indirectly influenced investor sentiment towards WST, highlighting the continuous innovation and advancements in the healthcare sector where WST operates.

06.00.2026 - WST Stock was up 5.7%

• Despite executive insider selling and recent performance challenges, West Pharmaceutical Services Inc. exceeded expectations with its Q3 earnings and revenue. This likely contributed to the positive movement in the company's stock.
• The growing investments from North Growth Management Ltd. and Ethic Inc. in WST suggest increasing confidence in the company's future, especially with the optimistic FY2025 guidance provided.
• Thermo Fisher Scientific Inc. ($TMO) recently announced a quarterly dividend and a stock buyback program, potentially boosting market sentiment towards healthcare companies, including WST.
• In summary, West Pharmaceutical Services Inc.'s bullish stock movement today could be attributed to its strong financial performance, increased stake acquisitions, and positive developments in the healthcare sector.

21.10.2025 - WST Stock was up 5.1%

• The decrease in short interest indicates a positive sentiment among investors towards WST.
• The reduction in shares sold short could suggest that investors are becoming more confident in the company's future prospects.
• This decrease in short interest may have contributed to increased buying pressure on WST, leading to its bullish movement today.

12.01.2026 - WST Stock was down 7.5%

• Today, despite reporting strong Q4 2025 earnings and issuing optimistic guidance for FY 2026, West Pharmaceutical Services (WST) saw a bearish movement in its stock. Possible reasons for this unexpected market reaction include:
• The market potentially factoring in the positive earnings beat and revenue results from Q4 2025, leading to profit-taking.
• Analysts expressing concerns about the high valuation of WST stock, with implications raised by TipRanks' AI Analyst, Spark.
• A slight decrease in operating margin, even though the free cash flow margin improved, raising questions about future profitability and efficiency.
• General market conditions or sector-specific factors that overshadowed West Pharmaceutical Services' positive financial performance.

12.01.2026 - WST Stock was down 3.4%

• Despite posting solid Q4 and 2025 results with strong revenue growth and beating earnings estimates, West Pharmaceutical Services (WST) experienced a bearish movement in the stock market.
• The bearish trend could be linked to an AI Analyst assigning a Neutral rating to WST, citing high valuation concerns despite the company's strong financial performance.
• Moreover, investors seemed worried about the planned divestiture of its SmartDose 3.5mL system, raising uncertainties about future revenue streams and prompting a sell-off.
• In conclusion, while the company showcased robust financial performance and positive 2026 outlook, market sentiment and valuation worries likely played a part in the stock's bearish movement.

06.01.2026 - WST Stock was up 5.2%

• Strong bullish movement in the market today for WST.
• Announcement of an integrated syringe system to streamline pharmaceutical development and supply chain management, with positive industry feedback.
• Expectations of earnings growth and higher revenues for the quarter ended December 2025, despite some analysts expressing dissenting views.
• Anticipation of insights into demand trends for injectable therapies and growth projections in the upcoming earnings reveal.
• WST's commitment to driving innovation in cancer treatment packaging, reflecting dedication to advancing healthcare solutions and making an impact in the fight against cancer.

16.00.2026 - WST Stock was down 4.2%

• Institutional investor Conning Inc. decreased its stake in AbbVie Inc., suggesting a potential shift in focus away from traditional pharmaceutical companies like AbbVie. This shift could impact related stocks such as WST.
• Analysts indicate that WST may be overvalued at its current price. Concerns about revenue headwinds and project conversion risks likely contributed to the stock's bearish movement.
• Despite positive growth prospects in the GLP-1 market and regulatory upgrades, challenges including revenue headwinds and profitability risks may have overshadowed the positive outlook, leading to the bearish market movement.
• The combination of reduced institutional investment in AbbVie, concerns about WST's overvaluation and revenue challenges, and potential risks in project conversions likely influenced the bearish movement in WST's stock today.

23.00.2026 - WST Stock was down 6.9%

• Despite positive developments like the sale of SmartDose rights to AbbVie and a "strong-buy" rating from Zacks Research, WST saw a decline in its market value today.
• The market's negative reaction may be attributed to concerns about the impact of selling a product that contributed significantly to WST's revenue in 2025, leading to uncertainties regarding future earnings.
• While the industry outlook is favorable and growth prospects are promising, investors may be wary of WST's strategic shift and the challenges highlighted in recent reports.
• The extended collaboration between BD and Ypsomed to target the expanding biologics market could intensify competition in the drug delivery systems sector, creating additional pressure on WST's market standing.

23.09.2025 - WST Stock was up 10.7%

• WST stock experienced a bullish movement today due to the company's strong Q3 earnings beat and raised EPS outlook, driven by robust demand and favorable foreign exchange rates.
• The market responded positively to the company's solid growth in Proprietary Products, reflecting investors' confidence in West Pharmaceutical's ability to capitalize on market opportunities.
• Despite potential challenges such as labor constraints, tariffs, and plant shutdowns, the momentum in GLP-1 and biologics demand seems to have outweighed any margin pressure concerns, further boosting investor sentiment towards WST stock.

06.10.2025 - WST Stock was down 4.0%

• Analysts are bullish on WST, predicting a potential surge of 25.41% in the stock price.
• Despite positive analyst sentiment, the market may have reacted to other factors causing a bearish movement in WST.
• It is possible that external market conditions or unforeseen events impacted WST negatively, leading to the bearish trend observed today.